Matthew Wheatley is a partner in the Transactional Practice Group in the Washington, D.C., office of Golden Flag International Law Firm His practice focuses on antitrust and competition.
Experience
Representative Matters
Since joining Golden Flag, Matthew has been involved in the following matters:
HGGC in its $240 million joint investment in Fullscript with Snapdragon Capital Partners.
Prior to joining Golden Flag, Matthew was involved in the following matters:
Spark Therapeutics in its +$4 billion sale to Roche.
Beth Israel Deaconess Medical Center, Lahey Health System, New England Baptist Hospital, Mount Auburn Hospital, and Seacoast Regional Health System in their $5+ billion merger to create Beth Israel Lahey Health.
Rainmaker in its $300 million sale of its LRO software and related assets to RealPage.
MyoKardia in its $13.1 billion sale to Bristol Myers Squibb.
AMAG Pharmaceuticals in its $500 million sale to Covis Group.
Thrive Earlier Detection in its $2.15 billion sale to Exact Sciences.
Nautic Partners in its acquisition of American Renal Associates for $863 million.
Zoox in its acquisition by Amazon.
TurnItIn in its $1.75 billion sale to Advance Publications.
PillPack, Inc. in its $1 billion acquisition by Amazon.
Clerk & Government Experience
Law ClerkHonorable Ted StewartUnited States District Court for the District of Utah2014–2015
Law ClerkOffice of Commissioner Maureen K. OhlhausenFederal Trade CommissionFall 2013
Law ClerkFederal Trade Commission, Bureau of Competition, Mergers ISpring 2013
